Identifying the NEAT1/miR-26b-5p/S100A2 axis as a regulator in Parkinson’s disease based on the ferroptosis-related genes
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0316179 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Taole Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Ferroptosis, Parkinson Disease, MicroRNAs, RNA, Long Noncoding. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Technology Major Project of Hunan Provincial Science and Technology Department.
Abstract (Originalsprache)
Objectives
Parkinson’s disease (PD) is a complex neurodegenerative disease with unclear pathogenesis. Some recent studies have shown that there is a close relationship between PD and ferroptosis. We aimed to identify the ferroptosis-related genes (FRGs) and construct competing endogenous RNA (ceRNA) networks to further assess the pathogenesis of PD.
Methods
Expression of 97 substantia nigra (SN) samples were obtained and intersected with FRGs. Bioinformatics analysis, including the gene set enrichment analysis (GSEA), consensus cluster analysis, weight gene co-expression network analysis (WGCNA), and machine learning algorithms, were employed to assess the feasible differentially expressed genes (DEGs). Characteristic signature genes were used to create novel diagnostic models and construct competing endogenous RNA (ceRNA) regulatory network for PD, which were further verified by in vitro experiments and single-cell RNA sequencing (scRNA-seq).
Results
A total of 453 DEGs were identified and 11 FRGs were selected. We sorted the entire PD cohort into two subtypes based on the FRGs and obtained 67 hub genes. According to the five machine algorithms, 4 features ( S100A2 , GNGT1 , NEUROD4 , FCN2 ) were screened and used to create a PD diagnostic model. Corresponding miRNAs and lncRNAs were predicted to construct a ceRNA network. The scRNA-seq and experimental results showed that the signature model had a certain diagnostic effect and lncRNA NEAT1 might regulate the progression of ferroptosis in PD via the NEAT1/miR-26b-5p/S100A2 axis.
Conclusion
The diagnostic signatures based on the four FRGs had certain diagnostic and individual effects. NEAT1/miR-26b-5p/S100A2 axis is associated with ferroptosis in the pathogenesis of PD. Our findings provide new solutions for treating PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.
- Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Centre for Medical Genetics, Central South University, Changsha, China.
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China.
- National Clinical Research Centre for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, China.
ORCID-Profile: Jifeng Guo
Förderung
- National Natural Science Foundation of China
- Technology Major Project of Hunan Provincial Science and Technology Department
Zitieren
APA
Li, T., & Guo, J. (2024). Identifying the NEAT1/miR-26b-5p/S100A2 axis as a regulator in Parkinson’s disease based on the ferroptosis-related genes. PLOS ONE. https://doi.org/10.1371/journal.pone.0316179
Vancouver
Li T, Guo J. Identifying the NEAT1/miR-26b-5p/S100A2 axis as a regulator in Parkinson’s disease based on the ferroptosis-related genes. PLOS ONE. 2024. doi:10.1371/journal.pone.0316179
BibTeX
@article{Li2024,
author = {Li, Taole and Guo, Jifeng},
title = {Identifying the NEAT1/miR-26b-5p/S100A2 axis as a regulator in Parkinson’s disease based on the ferroptosis-related genes},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0316179}
}
EUVIMED